CONMED (CNMD) Set to Announce Earnings on Wednesday

CONMED (NYSE:CNMD) is projected to release its Q3 2026 results after the market closes on Wednesday, October 28th. Analysts expect CONMED to announce earnings of $1.00 per share and revenue of $336.28 million for the quarter. CONMED has set its FY 2026 guidance at 4.480-4.600 EPS. Investors can check the company’s upcoming Q3 2026 earnings report page for the latest details on the call scheduled for Wednesday, October 28, 2026 at 4:30 PM ET.

CONMED (NYSE:CNMD) last released its earnings results on Wednesday, July 29th. The company reported $1.38 earnings per share for the quarter, topping analysts’ consensus estimates of $1.11 by $0.27. The firm had revenue of $343.49 million for the quarter, compared to the consensus estimate of $337.60 million. CONMED had a net margin of 4.12% and a return on equity of 14.31%. The company’s revenue was up .3% compared to the same quarter last year. During the same period in the prior year, the firm earned $1.15 EPS. On average, analysts expect CONMED to post $4.54 EPS for the current fiscal year and $4.73 EPS for the next fiscal year.

CONMED Stock Down 3.1%

Shares of CONMED stock opened at $47.73 on Tuesday. CONMED has a 1 year low of $31.44 and a 1 year high of $53.66. The firm has a market cap of $1.43 billion, a price-to-earnings ratio of 25.80, a PEG ratio of 2.25 and a beta of 0.94. The company has a 50-day moving average of $47.43 and a 200 day moving average of $41.41. The company has a debt-to-equity ratio of 0.63, a current ratio of 1.48 and a quick ratio of 0.69.

Analyst Ratings Changes

A number of equities research analysts have weighed in on the stock. Weiss Ratings upgraded shares of CONMED from a “sell (d+)” rating to a “hold (c-)” rating in a report on Wednesday, October 21st. BMO Capital Markets assumed coverage on shares of CONMED in a research note on Wednesday, July 8th. They set a “market perform” rating and a $36.00 target price for the company. Wall Street Zen upgraded shares of CONMED from a “hold” rating to a “buy” rating in a report on Monday, July 20th. Needham & Company LLC reiterated a “hold” rating on shares of CONMED in a report on Monday, July 13th. Finally, Bank of America reissued an “underperform” rating and issued a $40.00 price target on shares of CONMED in a research report on Monday, June 29th. Seven equities research analysts have rated the stock with a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the stock presently has an average rating of “Reduce” and a consensus target price of $41.40.

About CONMED

CONMED Corporation is a medical technology company that develops, manufactures, and sells surgical devices and related equipment. Its products are used by hospitals, ambulatory surgery centers, and other healthcare providers in orthopedic and general surgery procedures.

The company’s orthopedic portfolio includes arthroscopy systems, powered surgical instruments, sports medicine products, tissue ablation systems, implants, and related accessories. Its general surgery offerings include electrosurgical equipment, insufflation systems, smoke evacuation products, surgical visualization technologies, and devices used in minimally invasive procedures.

Founded in 1970, CONMED serves healthcare customers through direct sales and distribution channels in the United States and international markets.